Pressemitteilungen

BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients

: 07. Oktober 2019

San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, Inc. announced the first patient was enrolled and treated in the REVIVE-HF European study, a prospective multi-center, dual-arm randomized controlled study evaluating the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC^™ System compared to Guideline-Directed Medical Therapy (GDMT) or drug treatment.

: 23. September 2019

To demonstrate that treatment with the Revivent TC^TM System is more effective than Guideline Directed Medical Therapy (GDMT) for the treatment of ischemic heart failure.

: 16. September 2019

He will be focused on growth of the Revivent TC^TM TransCatheter Ventricular Enhancement System.

San Ramon, CA, USA – Sept. 16, 2019 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), announced today that Pedro Marques has been named Vice President of Sales for the European market.

: 06. August 2019

Chief Medical Officer for Europe and Chief Financial Officer named

San Ramon, CA, USA – August 6, 2019 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced two significant additions to its executive team.

: 28. Februar 2019

San Ramon, Calif., February 28, 2019 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced a significant reimbursement achievement. InEk, the German Institute for Hospital Remuneration, has reconfirmed the award of NUB Status 1 for the Revivent TC™ TransCatheter Ventricular Enhancement System.